<DOC>
	<DOCNO>NCT00434642</DOCNO>
	<brief_summary>This placebo-controlled , randomize , multicenter Phase III study evaluate safety efficacy bevacizumab , administer combination carboplatin gemcitabine , woman platinum-sensitive recurrent epithelial ovarian , primary peritoneal , fallopian tube carcinoma .</brief_summary>
	<brief_title>A Study Carboplatin Gemcitabine Plus Bevacizumab Patients With Ovary , Peritoneal , Fallopian Tube Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Signed Informed Consent Form Age â‰¥ 18 year Documented ovarian , primary peritoneal , fallopian tube carcinoma recur No prior chemotherapy recurrent set Measurable disease Recovered prior radiation therapy surgery Prior chemotherapy treatment recurrent ovarian , primary peritoneal , fallopian tube carcinoma History abdominal fistula , gastrointestinal perforation ( GIP ) , intraabdominal abscess Patients clinical symptom sign gastrointestinal ( GI ) obstruction require parenteral hydration , parenteral nutrition , tube feeding Patients evidence abdominal free air explain paracentesis recent surgical procedure Current , recent , planned participation experimental drug study History systemic bevacizumab ( Avastin ) vascular endothelial growth factor ( VEGF ) VEGF receptortargeted agent use Inadequately control hypertension Prior history hypertensive crisis hypertensive encephalopathy New York Heart Association Class II great congestive heart failure ( CHF ) History myocardial infarction unstable angina History stroke transient ischemic attack ( TIA ) Known central nervous system ( CNS ) disease except treated brain metastasis Significant vascular disease recent peripheral arterial thrombosis History hemoptysis Evidence bleed diathesis significant coagulopathy ( absence therapeutic anticoagulation )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Avastin</keyword>
	<keyword>Ovarian carcinoma</keyword>
	<keyword>Peritoneal carcinoma</keyword>
	<keyword>Peritoneal cancer</keyword>
	<keyword>Fallopian tube cancer</keyword>
	<keyword>Fallopian tube carcinoma</keyword>
	<keyword>OCEANS</keyword>
</DOC>